S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Diffusion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DFFN)

$1.45
-0.25 (-14.71 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$1.31
Now: $1.45
$1.60
50-Day Range
$1.47
MA: $1.94
$2.20
52-Week Range
$1.31
Now: $1.45
$11.00
Volume240,340 shs
Average Volume192,710 shs
Market Capitalization$6.80 million
P/E RatioN/A
Dividend YieldN/A
Beta0.06
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DFFN
CUSIPN/A
Phone434-220-0718

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share

Profitability

Net Income$-18,370,000.00

Miscellaneous

Employees10
Market Cap$6.80 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive DFFN News and Ratings via Email

Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter.


Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?

Diffusion Pharmaceuticals shares reverse split before market open on Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.06. View Diffusion Pharmaceuticals' Earnings History.

When is Diffusion Pharmaceuticals' next earnings date?

Diffusion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Diffusion Pharmaceuticals.

What price target have analysts set for DFFN?

1 brokers have issued 12 month target prices for Diffusion Pharmaceuticals' stock. Their predictions range from $10.00 to $10.00. On average, they anticipate Diffusion Pharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 589.7% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.

What is the consensus analysts' recommendation for Diffusion Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.

Has Diffusion Pharmaceuticals been receiving favorable news coverage?

Headlines about DFFN stock have trended very negative on Thursday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Diffusion Pharmaceuticals.

Are investors shorting Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 80,300 shares, a decrease of 19.9% from the August 30th total of 100,200 shares. Based on an average daily trading volume, of 65,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.8% of the shares of the stock are short sold. View Diffusion Pharmaceuticals' Current Options Chain.

Who are some of Diffusion Pharmaceuticals' key competitors?

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Coherus Biosciences (CHRS), Intercept Pharmaceuticals (ICPT), Verastem (VSTM), Agile Therapeutics (AGRX), Achaogen (AKAO), Fibrocell Science (FCSC), Lipocine (LPCN) and MEI Pharma (MEIP).

Who are Diffusion Pharmaceuticals' key executives?

Diffusion Pharmaceuticals' management team includes the folowing people:
  • Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 70)
  • Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 80)
  • Mr. William Karl Hornung, Chief Financial Officer (Age 50)
  • Mr. Thomas E. Byrne, Gen. Counsel (Age 62)
  • Dr. David Randolph Jones M.D., Sr. Medical Advisor (Age 56)

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $1.45.

How big of a company is Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals has a market capitalization of $6.80 million. The company earns $-18,370,000.00 in net income (profit) each year or ($6.08) on an earnings per share basis. Diffusion Pharmaceuticals employs 10 workers across the globe.View Additional Information About Diffusion Pharmaceuticals.

What is Diffusion Pharmaceuticals' official website?

The official website for Diffusion Pharmaceuticals is http://www.diffusionpharma.com/.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]


MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel